Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Ozempic (semaglutide), Wegovy, Mounjaro, and Zepbound are increasingly used for managing weight, diabetes, and related health issues. A common question among users is whether these medications interfere with oral contraceptives, potentially reducing their effectiveness and increasing the risk of unintended pregnancy. The interaction largely depends on the specific GLP-1 RA and dosage. Certain GLP-1 medications, notably tirzepatide, may delay gastric emptying, which can temporarily impact the absorption of concurrently administered oral medications, including hormonal contraceptives. Delayed gastric emptying means the medication stays longer in the stomach, potentially reducing how much of the hormone is absorbed into the bloodstream. However, clinical pharmacokinetic studies have demonstrated that drugs like semaglutide (Ozempic) do not significantly reduce the bioavailability of hormonal components such as ethinylestradiol and levonorgestrel, common in many birth control pills. This suggests that most users of semaglutide likely do not experience reduced contraceptive effectiveness. That said, caution is advised with medications like Zepbound, which may have a stronger effect on gastric emptying. Healthcare providers often recommend monitoring and possibly using backup contraceptive methods, especially during the initial period of GLP-1 RA therapy or when dosages are changed. In general, patients should inform their healthcare providers about all medications they use, including contraceptives. Pharmacists and prescribers can offer personalized advice and ensure contraceptive efficacy is maintained. In summary, while some GLP-1 receptor agonists can temporarily affect the absorption of oral contraceptives, not all have a clinically significant impact. Awareness and consultation with healthcare professionals ensure women using both GLP-1 medications and birth control maintain effective pregnancy prevention strategies.